QPPV.COM KNOWLEDGE ASSESSMENT

Guselkumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Guselkumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why can comparing the number of intestinal adverse-event reports between two biological classes be misleading without exposure denominators and indication context?

Spontaneous reports are never useful for signal detection Different classes may be used in different disease populations with different baseline risks and reporting opportunities Adverse-event reports are determined only by molecular target Indication is irrelevant once a medicine is authorised

Question 2 of 10 Which comparison between guselkumab and a p40-directed antibody is scientifically most accurate?

Both selectively inhibit IL-23 because p40 is unique to IL-23 Guselkumab targets p19 and leaves IL-12 signalling directly unblocked, whereas p40 blockade can inhibit both IL-12 and IL-23 signalling Guselkumab blocks IL-12 but not IL-23, whereas p40 antibodies block only IL-23 There is no mechanistic distinction because p19 and p40 are interchangeable subunits

Question 3 of 10 Which information would be most valuable when following up a serious infection suspected during guselkumab treatment?

Only the date of the most recent prescription Infection site, organism, microbiology or imaging, severity, concomitant immunosuppression and outcome Only whether the patient had previously used a topical medicine The patient's treatment preference without clinical details

Question 4 of 10 A patient develops an elevated ALT while receiving guselkumab. Which approach is most appropriate for causality and clinical assessment?

Attribute the elevation to guselkumab without further investigation Review baseline and peak liver tests, bilirubin, alkaline phosphatase, timing, symptoms, concomitant medicines and competing liver disease Disregard the result unless jaundice is present Assess only whether the patient received a subcutaneous dose

Question 5 of 10 Why should isolated liver-enzyme elevations not automatically be treated as equivalent to clinically important drug-induced liver injury in aggregate analysis?

All liver-enzyme elevations are unrelated to medicines The clinical significance depends on the pattern, magnitude, bilirubin, symptoms, timing and competing causes Only bilirubin is relevant to liver safety Clinical liver injury can be diagnosed from the indication alone

Question 6 of 10 Why should hypersensitivity surveillance for guselkumab include events occurring days after administration?

Delayed systemic reactions have been reported and may be missed if surveillance is restricted to the injection visit All delayed symptoms are necessarily hypersensitivity reactions Only delayed events are considered serious Immediate reactions cannot occur with biological medicines

Question 7 of 10 What is the key distinction between a medication-error report and a near-miss report involving guselkumab?

A medication error involves actual deviation or incorrect administration, whereas a near miss is intercepted before reaching the patient A near miss is always clinically more severe than an administered error Medication errors apply only to intravenous treatment There is no operational distinction between the two

Question 8 of 10 How should a positive anti-drug-antibody result generally be interpreted?

It automatically proves loss of efficacy and hypersensitivity It is clinically meaningful only in relation to titre, persistence, assay characteristics, drug exposure, efficacy and clinical findings It proves that the product was counterfeit It can be interpreted without considering adherence or disease activity

Question 9 of 10 What molecular feature most directly explains why guselkumab is classified as a selective IL-23 inhibitor rather than an IL-12/23 inhibitor?

It binds the p19 subunit, which is unique to IL-23 It binds the p40 subunit, which is shared by IL-12 and IL-23 It binds the IL-17 receptor on target cells It inhibits intracellular signalling downstream of both IL-12 and IL-23

Question 10 of 10 Which documentation would best improve the assessment of a suspected guselkumab hypersensitivity reaction?

A generic statement that the patient felt unwell Latency, clinical phenotype, treatment, recurrence after re-exposure, route or presentation and outcome Only the patient's diagnosis of psoriasis Only whether the reaction occurred in a hospital

Guselkumab: Classification, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings